Neuropsychiatric lupus erythematosus;Il lupus neuropsichiatrico

Reumatismo

Volumn 58, Issue 3, 2006, Pages 177-186

  Vadacca, M ^a   Buzzulini, F ^a   Rigon, A ^a   Coppolino, G ^a   Palma Modoni, A ^a   Massa, R ^b   Afeltra, A ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiphospholipid antibodies; Neuroimaging; Neuropsychiatric manifestations; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; NEUROLEPTIC AGENT; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUROIMAGING; NEUROPSYCHIATRIC LUPUS ERYTHEMATOSUS; PATHOGENESIS; PREVALENCE; REVIEW; SERODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-ANXIETY AGENTS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPSYCHOTIC AGENTS; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MEDICAL HISTORY TAKING; METHOTREXATE; PLASMAPHERESIS; PREVALENCE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33749014148     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Johnson RT, Richardson EP. The neurologic manifestations of systemic lupus erythematosus: a clinical-pathological study of 24 cases and review of the literature. Medicine (Baltimore) 1968; 47: 337-69.
2. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979; 8: 212-21.
3. Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19: 732-41.
4. Kaposi M. Neue beitrage zur kenntnis des lupus erythematosus. Arch Dermat Syph 1872; 4: 36-79.
5. Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci 1895; 110: 629-46.
6. Osler W. The visceral lesions of the erythema group. Br J Dermatol 1900; 12: 228-45.
7. Osler W. On the visceral manifestations of erythema group of skin diseases. Trans Assoc Am Physicians 1903; 18: 599.
8. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus: computer analysis of 520 cases. JAMA 1964; 190: 104-11.
9. Klippel JH, Zvaifler NJ. Neuropsychiatric abnormalities in systemic lupus erythematosus. Clin Rheum Dis 1975; 1: 621-38.
10. Vitali C, Bencivelli W, Isemberg DA, Smolen JS, Snaith ML, Sciuto M, et al. European Consensus Study Group for Disease Activity in SLE (1992). Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European workshop for Rheumatology Research. A descriptive analysis of 704 european lupus patients. Clin Exp Rheumatol 1992; 10: 527-39.
11. West SG, Emlen W, Werner MH, Kottizin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995; 99: 153-63.
12. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 1995; 122: 940-50.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 17-25.
14. Hughes GVR, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-9.
15. Singer J, Denburg JA and Ad Hoc Neuropsychiatric Lupus Workshop Group. Diagnostic Criteria for neuropsychiatric systemic lupus erythmatosus: the results of a consensus meeting. J Rheumatol 1990; 17: 1397-402.
16. ACR ad hoc Commettee on Neuropsychiatric lupus nomenclature. The American College of Rheumatology Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
17. Russell PW, Haserick JR. Epilepsy in systemic lupus erythematosus. AMA Arch Intern Med 1951; 88: 78-92.
18. Hughes GRV. Epilepsy: an early symptom of systemic lupus erythematosus. Letters J Neurol Neurosurg Psychiatry. 1985; 48: 185-92.
19. McCune WJ, Golbus J. Neuropsychiatric lupus. Rheum Dis North Am 1988; 14: 149-67.
20. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20: 129-58.
21. Brey RL, Petri MA. Neuropsychiatric systemic lupus erythematosus: miles to go before we sleep. Neurology 2003; 61: 9-10.
22. Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F, et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-10.
23. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 2004; 43: 1555-60.
24. Hanly JG, McCurdy G, Fourgere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Reumatol 2004; 31: 2156-62.
25. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestation in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-92.
26. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500.
27. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndrome in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214-20.
28. Sibbit Jr W, Brandt JR, Johnson CR. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29: 1536-42.
29. Hermosillo-Romo D, Brey RL. Diagnosis and managment of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol 2002; 16: 229-44.
30. Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanism of clinical syndromes: a literature investigation. Rheumatology 2002; 41: 619-30.
31. Afeltra A, Vadacca M, Galluzzo S, Conti L, Mitterhofer AP, Ferri GM, et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arth ritis Rheum 2005; 53: 452-9.
32. Jennekens FGI, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology 2002; 41: 605-18.
33. Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations in systemic lupus erythematosus. Am J Med 1981; 70: 240-6.
34. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317: 265-71.
35. Eber T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 2005; 14: 571-5.
36. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best practice & Clinical research Rheumatology 2005; 19: 799-821.
37. Weiner SM, Klein R, Berg PA. A longitudinal study of autoantibodies against central nervous system tissue and gangliosides in connective tissue diseases. Rheumatol Int 2000; 19: 83-8.
38. Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Progress in Neurobiology 1998; 54: 581-618.
39. DeGiorgio LA, Konstantinov KN, Lee SC, Hardiu JA, Volpe BT, Diamone B, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine 2001; 7: 1189-93.
40. Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12: 392-98.
41. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Pini C, et al. Serum anti-b2GPI antibodies from patients with antiphospholipid antibody sindrome bind central nervous system cells. J Autoimmunity 1998; 1: 425-9.
42. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8: 127-33.
43. Baraczka K, Nekam K, Poszony T, Szuts I, Ormos G. Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and SLE. Eur J Neurol 2004; 11: 37-42.
44. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000; 9: 498-503.
45. Dellalibera-Joviliano R, Dos Reis ML, Cunha Fde Q, Donadi EA. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J Rheumatol 2003; 30: 485-92.
46. Rood MJ, Keijsers V, van der Linden MW, Tong TQ, Borggreve SE, Verweij CL, et al. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis 1999; 58: 85-9.
47. Peterson P, Axford J, Isenberg D. Imaging in CNS lupus. Best Prat Res Clin Rheumatol 2005; 19: 727-39.
48. Govoni M, Castellino G, Padovan M, Borrelli M, Trotta F. Recent advances and future prospective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus 2004; 13: 149-58.
49. Sibbitt WL, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2026-38.
50. Amoroso A, Del Porto F, Garzia P, Mariotti A, Addessi MA, Afeltra A. Primary antiphospholipid sindrome and cerebral atrophy: a rare association? Am J Med Sci 1999; 317: 425-8.
51. Peterson PL, Howe FA, Clarck CA, Axford JS. Quantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus. Lupus 2003; 12: 897-902.
52. Miller DH, Buchanan N, Barker G. Gadolinium enhances magnetic resonance imaging in the central nervous system in systemic lupus erythematosus. J Neurology 1992; 239: 460-4.
53. Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL Jr. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999; 26: 81-5.
54. Sibbitt WL, Haseler LJ, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff NA. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR 1994; 15: 923-8.
55. Govoni M, Colamussi P, Tamarozzi R, Trotta F. L'imaging nel neuro-LES. Reumatismo 2000; 52(Suppl 2): 123-9.
56. Bosma GP, Rood MJ, Zwinderman AH, Huizinga TW, van Buchen MA. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum 2000; 43: 48-54.
57. Bosma GP, Middelkoop HA, Rood MJ, Bollen EL, Huizinga TW, von Buchen MA. Association of global brain damage and clinical functioning in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2665-72.
58. Steens SC, Admiral-Behlonl F, Bosma GP, Stemp-Beekmam GH, Olofsen H, le Cessie S, Huizinga TW, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004; 50: 2877-81.
59. Padovan M, Locaputo A, Rizzo N, Govoni M, Trotta F. Il neuroimaging funzionale nella valutazione del coinvolgimento neurologico in corso di lupus eritematoso sistemico. Risultati preliminari. Reumatismo 2004; 56: 24-30.
60. Kovacs JA, Urowitz MB, Gladman DD, Zeman R. The use of single photon emission computed tomography in neuropsychiatric SLE: a pilot study. J Rheumatol 1995; 22: 1247-53.
61. Borchers AT, Aoki AC, Naguwaa SM, Keenb CL, Shoenfeld Y, Gershwina ME. Neuropsychiatric features of systemic lupus erythematosus. Autoim Reviews 2005; 4: 329-44.
62. Kao CH, Ho YJ, Lan JL, Changlai SP, Liao KK, Chieng PU. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus in patients with normal brain magnetic resonance imaging findings. Arthritis Rheum 1999; 42: 61-8.
63. Tomietto P, Annese V, D'Agostini S, Gremese E, Di Poi E, Ferraccioli G. Test neuropsicologici, RMN e SPECT nella valutazione del danno cerebrale nel LES. Reumatismo 2003; 55: 171-80.
64. Lòpez Longo FJ, Caro N. Cerebral hypoperfusion detected by SPECT in patients with systemic lupus erythematosus is related to clinical activity and cumulative tissue damage. Lupus 2003; 12: 813-9.
65. Gladman DD, Urowitz MB, Ong A, Gough J, Mackinnon A. Lack of correlation between the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996; 14: 305-8.
66. Ilowite NT. Premature atherosclerosis in systemic lupus erythematosus. J Rheumatol 2000; 27: 15-19.
67. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12: 935-42.
68. Sanna G, Khamashta MA. Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus. Lupus 2003; 12: 1-2.
69. Ramos PC, Mendez MJ, Ames PR, Khamashta MA, Hughes GR. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 295-9.
70. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-7.
71. Hanly JG. Neuropsychiatric lupus. Curr Rheum Rep 2001; 3: 205-12.